|Other Names||Cytochrome P450 2F1, CYPIIF1, CYP2F1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7883b was selected from the C-term region of human CYP2F1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May be involved in the metabolism of various pneumotoxicants including naphthalene. Is able to dealkylate ethoxycoumarin, propoxycoumarin, and pentoxyresorufin but possesses no activity toward ethoxyresorufin and only trace dearylation activity toward benzyloxyresorufin. Bioactivates 3- methylindole (3MI) by dehydrogenation to the putative electrophile 3-methylene-indolenine.|
|Cellular Location||Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein|
|Tissue Location||Expressed in lung. Rarely detected in liver and placenta.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CYP2F1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to dehydrogenate 3-methylindole, an endogenous toxin derived from the fermentation of tryptophan, as well as xenobiotic substrates such as naphthalene and ethoxycoumarin.
Tournel,G., Xenobiotica 37 (12), 1433-1438 (2007)Tournel,G., Mutat. Res. 617 (1-2), 79-89 (2007)Nelson,D.R., Pharmacogenetics 14 (1), 1-18 (2004)
If you have any additional inquiries please email technical services at email@example.com.